FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3091810963> ?p ?o ?g. }

• W3091810963 abstract "Abstract Issue Innovative contracting models are developed to ease price-setting negotiations in case an extremely expensive drug has not proven sufficient efficiency in clinical trials. As disruptive HIV treatments are expected in the near future, French patient organizations evaluated the ability of these innovative contracts to ensure accessible medicines at a fair price. Description Performance-based schemes condition prices paid by the State to the efficiency of the medicine observed through real-world data. In France, thirteen performance-based contracts have been concluded between 2008 and 2015. They are presented as a triple solution: innovative treatments are available to patients, manufacturers access markets, and states ensure healthcare within limited budgets. Establishing the added value of these models implies determining if they allow rapid access to treatments with substantial savings for payers, while ensuring rigorous price and cost transparency. Results Performance-based contracts indeed ensure patient access to treatments, but other mechanisms (such as temporary use authorizations) already serve this purpose. Regarding expenditure reduction however, these schemes have not proven their worth. The Court of Auditors' evaluation showed they do not generate substantial savings, as final prices correspond to those that would have applied with the European price guarantee. Lastly, as contracts are protected by business secrecy, the public cannot access neither to actual prices negotiated by payers, nor the amount of public investment that have been used for the research and development of the drug. Lessons The derogatory nature of performance contracts invites us to consider them on a case-by-case basis if ensuring access to a specific innovation is necessary. These contracts are certainly innovative, but they cannot be presented as technologies providing access at a fair price. Finally, their contractual and derogatory nature raises serious transparency issues. Key messages Performance-based contracts should be considered as alternatives to existing administrative channels provided that they lead to substantial savings and are drawn up in full transparency. Patient organizations need to assess innovative schemes such as performance-based contracting to ensure access to treatments without undermining historical struggles for fair and transparent pricing." @default.
• W3091810963 created "2020-10-15" @default.
• W3091810963 creator A5034847312 @default.
• W3091810963 creator A5046538500 @default.
• W3091810963 creator A5085197782 @default.
• W3091810963 date "2020-09-01" @default.
• W3091810963 modified "2023-09-25" @default.
• W3091810963 title "Ensuring access to medicines at a fair price? Innovative contracting experiences in France" @default.
• W3091810963 doi "https://doi.org/10.1093/eurpub/ckaa165.071" @default.
• W3091810963 hasPublicationYear "2020" @default.
• W3091810963 type Work @default.
• W3091810963 sameAs 3091810963 @default.
• W3091810963 citedByCount "0" @default.
• W3091810963 crossrefType "journal-article" @default.
• W3091810963 hasAuthorship W3091810963A5034847312 @default.
• W3091810963 hasAuthorship W3091810963A5046538500 @default.
• W3091810963 hasAuthorship W3091810963A5085197782 @default.
• W3091810963 hasBestOaLocation W30918109631 @default.
• W3091810963 hasConcept C10138342 @default.
• W3091810963 hasConcept C121955636 @default.
• W3091810963 hasConcept C144133560 @default.
• W3091810963 hasConcept C162118730 @default.
• W3091810963 hasConcept C17744445 @default.
• W3091810963 hasConcept C199521495 @default.
• W3091810963 hasConcept C199539241 @default.
• W3091810963 hasConcept C199776023 @default.
• W3091810963 hasConcept C27548731 @default.
• W3091810963 hasConcept C2776452267 @default.
• W3091810963 hasConcept C2780233690 @default.
• W3091810963 hasConcept C38652104 @default.
• W3091810963 hasConcept C41008148 @default.
• W3091810963 hasConcept C63149375 @default.
• W3091810963 hasConcept C94625758 @default.
• W3091810963 hasConceptScore W3091810963C10138342 @default.
• W3091810963 hasConceptScore W3091810963C121955636 @default.
• W3091810963 hasConceptScore W3091810963C144133560 @default.
• W3091810963 hasConceptScore W3091810963C162118730 @default.
• W3091810963 hasConceptScore W3091810963C17744445 @default.
• W3091810963 hasConceptScore W3091810963C199521495 @default.
• W3091810963 hasConceptScore W3091810963C199539241 @default.
• W3091810963 hasConceptScore W3091810963C199776023 @default.
• W3091810963 hasConceptScore W3091810963C27548731 @default.
• W3091810963 hasConceptScore W3091810963C2776452267 @default.
• W3091810963 hasConceptScore W3091810963C2780233690 @default.
• W3091810963 hasConceptScore W3091810963C38652104 @default.
• W3091810963 hasConceptScore W3091810963C41008148 @default.
• W3091810963 hasConceptScore W3091810963C63149375 @default.
• W3091810963 hasConceptScore W3091810963C94625758 @default.
• W3091810963 hasIssue "Supplement_5" @default.
• W3091810963 hasLocation W30918109631 @default.
• W3091810963 hasOpenAccess W3091810963 @default.
• W3091810963 hasPrimaryLocation W30918109631 @default.
• W3091810963 hasRelatedWork W1516349837 @default.
• W3091810963 hasRelatedWork W2094239534 @default.
• W3091810963 hasRelatedWork W2106370154 @default.
• W3091810963 hasRelatedWork W2273619562 @default.
• W3091810963 hasRelatedWork W2462004645 @default.
• W3091810963 hasRelatedWork W2554135412 @default.
• W3091810963 hasRelatedWork W2608805455 @default.
• W3091810963 hasRelatedWork W3137219336 @default.
• W3091810963 hasRelatedWork W4210809321 @default.
• W3091810963 hasRelatedWork W4362645956 @default.
• W3091810963 hasVolume "30" @default.
• W3091810963 isParatext "false" @default.
• W3091810963 isRetracted "false" @default.
• W3091810963 magId "3091810963" @default.
• W3091810963 workType "article" @default.